Prior failed checkpoint inhibitor

Phase 3

Prior failed checkpoint inhibitor is one of 12 therapeutic programs targeting NSCLC Stage IV. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

NSCLC Stage IVRecruiting

NSCLC Stage IVPhase 3

Recruiting

Competition

Competitive Landscape

11 competitors in NSCLC Stage IV

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

1 2

Taxotere

AAvyxa

Phase 3

1 3

Libtayo

Regeneron

Phase 2

1 4

Taxol

Teva

Phase 2

1 5

Keytruda

Merck & Co.

Phase 2

1 6

N-803

IImmunityBio, Inc.

Phase 3

1 7

Alimta

SShawn Eagle

Phase 2

1 8

Paraplatin

AAvyxa

Phase 2

1 9

Krazati

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 10

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 3Recruiting

NSCLC Stage IV

NCT06745908

Clinical

Trials by Indication[1]

NSCLC Stage IV1 trial

Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

Recruiting·IImmunityBio, Inc.·Phase 3·NCT06745908·507 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Prior failed checkpoint inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Prior failed checkpoint inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — ImmunityBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: IImmunityBio, Inc.

Prior failed checkpoint inhibitor

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

NSCLC Stage IV1 trial

References

Drug Info

Quick Facts

Related News